RCS - Kanabo Group PLC - Investor Webinar hosted by Vox Markets

KanaboAnnouncement

30/09/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220930:nRSd2470Ba&default-theme=true

RNS Number : 2470B  Kanabo Group PLC  30 September 2022

Kanabo Group Plc

("Kanabo" or the "Company")

 

Investor Webinar and Q&A

 

 

Kanabo Group plc (LSE:KNB) the pan-European medical cannabis company that
focuses on developing and commercialising cannabis-derived products for
medical patients and wellness CBD consumers, announces Avihu Tamir, Group CEO,
and Suleman Sacranie, Founder of the GP Service, will provide an investor
presentation relating to the Group's recently announced Unaudited Half Yearly
results and updated strategy via Vox Markets on Thursday October 6th at
5.30PM.

 

The presentation is open to all existing and potential shareholders, subject
to registration and will be followed by a Q&A session. Questions can be
submitted ahead of the event to Kat Perez, kperez@voxmarkets.co.uk
(mailto:kperez@voxmarkets.co.uk)

To register for the presentation, please visit:

 

https://us02web.zoom.us/webinar/register/WN_kF4Gah7xTxuhUg7ZmppznQ
(https://us02web.zoom.us/webinar/register/WN_kF4Gah7xTxuhUg7ZmppznQ)

 

Those who follow Kanabo Group plc on the Vox Markets platform will receive a
registration email.

 

 

For further information, please visit http://www.kanabogroup.com/ or contact
the following:

 Kanabo Group Plc                            Via Vox Markets
 Avihu Tamir, CEO
 Peterhouse Capital Ltd (Financial Adviser)  Tel: +44 (0)20 7469 0930
 Eran Zucker / Lauren Riley
 Peterhouse Capital Ltd (Corporate Broker)   Tel: +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow / Duncan Vasey / Martin Lampshire
 Vox Markets (Investor Relations)            KanaboGroup@voxmarkets.co.uk
 Kat Perez                                   kperez@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is a leading developer and distributer of cannabis-derived
products and inhalation technologies for medical patients and non-THC products
for CBD consumers. Kanabo Group Plc, which was the first medicinal cannabis
company to complete an IPO on the London Stock Exchange, is a vertically
integrated platform comprising cultivation consultancy, product R&D and
formula development, and marketing and distribution. Its subsidiaries include:

·    Kanabo Agritec Ltd, a cultivation consultancy supporting cannabis
businesses in developing new farms through infrastructure, research, and
product guidance. These farms deliver high-quality raw materials for Kanabo's
formulas and product line.

·    Kanabo Research Ltd, a wholly owned subsidiary of Kanabo Group Plc,
responsible for R&D, regulation, and quality assurance procedures.

·    The GP Service - a Kanabo Group Plc owned telehealth provider,
offering NHS approved online consultations, online prescriptions, treatment
forms and access to both Kanabo medical-cannabis & wellbeing CBD products.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFDAIIAFIF